Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.

Date publication

juin 2021

Journal

Thrombosis research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr GALLAND Loïck

Tous les auteurs :
Deschênes-Simard X, Richard C, Galland L, Blais F, Desilets A, Malo J, Cvetkovic L, Belkaid W, Elkrief A, Gagné A, Hamel MA, Orain M, Joubert P, Ghiringhelli F, Routy B, Blais N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34246011

Résumé

Venous thrombotic events (VTEs) are a frequent complication of non-small cell lung cancer (NSCLC) and are associated with increased morbidity. Immune checkpoint inhibitors (ICIs) are revolutionizing the management of NSCLC, but little is known about their impact on thrombosis. This study aims to define the incidence and clinical relevance of VTEs in NSCLC patients receiving these treatments.

Mots clés

Checkpoint inhibitors, Deep vein thrombosis, Immunotherapy, Non-small cell lung cancer, Pulmonary embolism, Thrombosis

Référence

Thromb Res. 2021 Jun 29;205:29-39